 Antineoplastic Agents
"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antitumor Drugs
- Drugs, Antitumor
- Antitumor Agents
- Agents, Antitumor
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 6 | 6 | 12 | | 1981 | 5 | 3 | 8 | | 1982 | 9 | 4 | 13 | | 1983 | 6 | 1 | 7 | | 1984 | 3 | 0 | 3 | | 1985 | 2 | 1 | 3 | | 1986 | 4 | 2 | 6 | | 1987 | 3 | 2 | 5 | | 1988 | 6 | 0 | 6 | | 1989 | 6 | 2 | 8 | | 1990 | 2 | 3 | 5 | | 1991 | 3 | 1 | 4 | | 1992 | 6 | 5 | 11 | | 1993 | 7 | 1 | 8 | | 1994 | 12 | 2 | 14 | | 1995 | 6 | 2 | 8 | | 1996 | 13 | 3 | 16 | | 1997 | 8 | 1 | 9 | | 1998 | 24 | 6 | 30 | | 1999 | 10 | 9 | 19 | | 2000 | 19 | 9 | 28 | | 2001 | 24 | 7 | 31 | | 2002 | 41 | 14 | 55 | | 2003 | 34 | 12 | 46 | | 2004 | 43 | 14 | 57 | | 2005 | 35 | 21 | 56 | | 2006 | 42 | 20 | 62 | | 2007 | 46 | 20 | 66 | | 2008 | 34 | 19 | 53 | | 2009 | 44 | 25 | 69 | | 2010 | 59 | 28 | 87 | | 2011 | 61 | 18 | 79 | | 2012 | 56 | 25 | 81 | | 2013 | 47 | 21 | 68 | | 2014 | 66 | 23 | 89 | | 2015 | 71 | 32 | 103 | | 2016 | 60 | 32 | 92 | | 2017 | 40 | 25 | 65 | | 2018 | 36 | 20 | 56 | | 2019 | 15 | 10 | 25 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Wu TD, Madireddi S, de Almeida PE, Banchereau R, Chen YJ, Chitre AS, Chiang EY, Iftikhar H, O'Gorman WE, Au-Yeung A, Takahashi C, Goldstein LD, Poon C, Keerthivasan S, de Almeida Nagata DE, Du X, Lee HM, Banta KL, Mariathasan S, Das Thakur M, Huseni MA, Ballinger M, Estay I, Caplazi P, Modrusan Z, Delamarre L, Mellman I, Bourgon R, Grogan JL. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature. 2020 03; 579(7798):274-278.
-
Navari RM. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. Expert Opin Drug Saf. 2020 Feb; 19(2):205-210.
-
Guadamuz JS, Ozenberger K, Qato DM, Ko NY, Saffore CD, Adimadhyam S, Cha AS, Moran KM, Sweiss K, Patel PR, Chiu BC, Calip GS. Mediation analyses of socioeconomic factors determining racial differences in the treatment of diffuse large B-cell lymphoma in a cohort of older adults. Medicine (Baltimore). 2019 Nov; 98(46):e17960.
-
Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 10 31; 381(18):1728-1740.
-
Navari RM. The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy. Expert Opin Drug Saf. 2019 Dec; 18(12):1127-1132.
-
van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P, Schilsky RL, de Leng WWJ, Huitema ADR, Nuijen B, Nederlof PM, van Herpen CML, de Groot DJA, Devriese LA, Hoeben A, de Jonge MJA, Chalabi M, Smit EF, de Langen AJ, Mehra N, Labots M, Kapiteijn E, Sleijfer S, Cuppen E, Verheul HMW, Gelderblom H, Voest EE. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019 10; 574(7776):127-131.
-
Jelinek MJ, Armstrong SA, Patel JD, Subramaniam DS. Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy. Clin Lung Cancer. 2019 11; 20(6):e597-e600.
-
Chow R, Aapro M, Navari RM, Gralla R, Chiu N, Chiu L, Chan S, Popovic M, Lam H, Lock M, DeAngelis C. Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis. Crit Rev Oncol Hematol. 2019 Oct; 142:164-186.
-
Flood BA, Higgs EF, Li S, Luke JJ, Gajewski TF. STING pathway agonism as a cancer therapeutic. Immunol Rev. 2019 07; 290(1):24-38.
-
Liu JF, Gordon M, Veneris J, Braiteh F, Balmanoukian A, Eder JP, Oaknin A, Hamilton E, Wang Y, Sarkar I, Molinero L, Fassò M, O'Hear C, Lin YG, Emens LA. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol. 2019 08; 154(2):314-322.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|